Senior lecturer in the HI-TIDE Platform, Department of Oncology UNIL-CHUV

UNIL is a leading international teaching and research institution, with over 5,000 employees and 15,500 students split between its Dorigny campus, CHUV and Epalinges. As an employer, UNIL encourages excellence, individual recognition and responsibility. T he Faculty of Biology and Medicine (FBM) of the University of Lausanne is inviting applications for position of:

Senior lecturer (MER1)

in the HI-TIDE Platform, Department of Oncology UNIL-CHUV,

Ludwig Institute for Cancer Research

Starting date : to be agreed                                                                    

Place : Lausanne, Switzerland

The Human Integrated Tumor Immunology Discovery Engine (Hi-TIDe) is an innovative multi-group research program of the Ludwig Branch Lausanne, where discovery and technology development are pursued through team science. It was founded and is directed by Pr George Coukos.

Main missions:

• Develop and optimize standard operating procedures for T-cell design and expansion, and for the adoption of T-cell transfer. Assume responsibility for teaching students in biology or medicine.

Desired profile:

• PhD in molecular biology and/or biochemistry. Ability to work interdisciplinarily. Demonstrated ability to supervise and manage a group of at least 10 to 15 scientists in both research and clinical settings and in the development of new cellular therapeutic strategies. Strong communication and interpersonal skills, ability to resolve conflicts and effectively function in a shared goal-oriented team environment. At least 15 years research experience in the field of T cell engineering and cancer immunotherapy, including in vitro functional testing of gene-modified lymphocytes and their evaluation in murine tumor models. Expertise in functional assays including T-cell proliferation, cytokine production, target cell killing, phenotype characterization and use of necessary equipment such as flow cytometer, IncuCyte, etc. Recognized expertise in the development of novel anti-tumor cell therapies. Excellent demonstrated ability to collaborate with clinicians as well as bioinformaticians, systems and computational modelers and ethical and regulatory authorities for translational activities. Willingness to actively participate in the development of an academic training program. Knowledge of Swiss laws pertaining to in vivo studies and LTK1 and LTK2 training to undertake and direct mouse tumor model work, respectively. Knowledge and know-how in both non-viral and viral engineering strategies of primary immune cells including lentivirus, retrovirus, Sleeping Beauty and CRISPR – Cas9. Expertise in T cell receptor (TCR) and chimeric antigen receptor (CAR) design and co-engineering strategies to improve the efficacy and safety of engineered T cells for cancer immunotherapy. Expertise in T-cell culture/expansion for adoptive T cell transfer. Extensive experience in the translation of research into clinical activities Good knowledge in French (LM or minimum B2, C1 ideal) or ability to acquire it quickly. Experience in supervising or co-supervising master and doctoral thesis. Ability to develop clinical research programs supported by expert external funding. Ability to function in a dynamic work environment with tight timelines. Promising track record in leading independent research, or participation in funded research projects or research programs

Contact: Pr Tatiana Petrova ([email protected]) Director of the DOF and Pr George Coukos ([email protected]), Director of the DO.

Applications, in English, should include 1) a motivation letter, 2) a curriculum vitae, 3) a list of publications highlighting the five most significant ones, 4) a brief statement of the past and future research, 5) a summary of previous teaching experience, 6) your vision of the field's development in the mid/long term, 7) names and contact information of at least three references, 8) a copy of diplomas and a valid ID card.

Full applications should be submitted online as a single PDF file to the University’s website by April 21st 2024 (23:59 GMT+1). Only applications sent through this site will be considered.

The job description is available on the University’s website.

UNIL is committed to promoting gender equality and diversity and strongly encourages applications from female candidates www.unil.ch/egalite .